Clinical Trial Update: A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients [Phase 2]

View source ↗

Summary

This document reports a completed Phase II pilot study evaluating tolerability and potential efficacy of subcutaneously administered recombinant human insulin-l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• CEP-151 (rhIGF-1) (insulin-like growth factor-1, recombinant human)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED